Targeted Therapy—Possible New Therapeutic Option for Malignant Mesothelioma?

REFERENCES

• Tossavainen A. Global use of asbestos and the incidence of mesothelioma. Int. J. Occup. Environ. Health 2004; 10: 22–25
   PubMed Web of Science ®Google Scholar
• Wagner J. C., Sleggs C. A., Marchand P. Diffuse pleural mesothelioma and asbestos exposure in the North Western Cape Province. Br. J. Ind. Med. 1960; 17: 260–271
   PubMedGoogle Scholar
• Kamp D. W., Israbian V. A., Preusen S. E., Zhang C. X., Weitzman S. A. Asbestos causes DNA strand breaks in cultured pulmonary epithelial cells: role of iron-catalyzed free radicals. Am. J. Physiol. 1995; 268: L471–L480
   PubMed Web of Science ®Google Scholar
• Ault J. G., Cole R. W., Jensen C. G., Jensen L. C., Bachert L. A., Rieder C. L. Behavior of crocidolite asbestos during mitosis in living vertebrate lung epithelial cells. Cancer Res. 1995; 55: 792–798
   PubMed Web of Science ®Google Scholar
• Hilliard A. K., Lovett J. K., McGavin C. R. The rise and fall in incidence of malignant mesothelioma from a British Naval Dockyard, 1979–1999. Occup. Med. (Lond) 2003; 53: 209–212
   PubMed Web of Science ®Google Scholar
• Sun X., Dobra K., Bjornstedt M., Hjerpe A. Upregulation of 9 genes, including that for thioredoxin, during epithelial differentiation of mesothelioma cells. Differentiation 2000; 66: 181–188
   PubMed Web of Science ®Google Scholar
• Kahlos K., Soini Y., Saily M., Koistinen P., Kakko S., Paakko P., Holmgren A., Kinnula V. L. Up-regulation of thioredoxin and thioredoxin reductase in human malignant pleural mesothelioma. Int. J. Cancer 2001; 95: 198–204
   PubMed Web of Science ®Google Scholar
• Rihn B. H., Mohr S., McDowell S. A., Binet S., Loubinoux J., Galateau F., Keith G., Leikauf G. D. Differential gene expression in mesothelioma. FEBS Lett. 2000; 480: 95–100
   PubMed Web of Science ®Google Scholar
• Mohr S., Rihn B. [Gene expression profiling in human mesothelioma cells using DNA microarray and high-density filter array technologies]. Bull. Cancer 2001; 88: 305–313
   PubMed Web of Science ®Google Scholar
• Mohr S., Bottin M. C., Lannes B., Neuville A., Bellocq J. P., Keith G., Rihn B. H. Microdissection, mRNA amplification and microarray: a study of pleural mesothelial and malignant mesothelioma cells. Biochimie 2004; 86: 13–19
   PubMed Web of Science ®Google Scholar
• Nymark P., Lindholm P. M., Korpela M. V., Lahti L., Ruosaari S., Kaski S., Hollmen J., Anttila S., Kinnula V. L., Knuutila S. Gene expression profiles in asbestos-exposed epithelial and mesothelial lung cell lines. BMC Genomics 2007; 8: 62
   PubMed Web of Science ®Google Scholar
• Ceresoli G. L., Locati L. D., Ferreri A. J., Cozzarini C., Passoni P., Melloni G., Zannini P., Bolognesi A., Villa E. Therapeutic outcome according to histologic subtype in 121 patients with malignant pleural mesothelioma. Lung Cancer 2001; 34: 279–287
   PubMed Web of Science ®Google Scholar
• Sun X., Wei L., Liden J., Hui G., Dahlman-Wright K., Hjerpe A., Dobra K. Molecular characterization of tumor heterogeneity and malignant mesothelioma cell differentiation by gene profiling. J. Pathol. 2005; 207: 91–101
   PubMed Web of Science ®Google Scholar
• Holmgren A., Bjornstedt M. Thioredoxin and thioredoxin reductase. Methods Enzymol 1995; 252: 199–208
   PubMed Web of Science ®Google Scholar
• Arner E. S., Holmgren A. The thioredoxin system in cancer. Sem. Cancer Biol. 2006; 16: 420–426
   PubMed Web of Science ®Google Scholar
• Bjornstedt M., Kumar S., Bjorkhem L., Spyrou G., Holmgren A. Selenium and the thioredoxin and glutaredoxin systems. Biomed Environ. Sci. 1997; 10: 271–279
   PubMedGoogle Scholar
• Marzano C., Gandin V., Folda A., Scutari G., Bindoli A., Rigobello M. P. Inhibition of thioredoxin reductase by auranofin induces apoptosis in cisplatin-resistant human ovarian cancer cells. Free Radic. Biol. Med. 2007; 42: 872–881
   PubMed Web of Science ®Google Scholar
• Rigobello M. P., Scutari G., Boscolo R., Bindoli A. Induction of mitochondrial permeability transition by auranofin, a gold(I)-phosphine derivative. Br. J. Pharmacol. 2002; 136: 1162–1168
   PubMed Web of Science ®Google Scholar
• Powis G., Kirkpatrick D. L. Thioredoxin signaling as a target for cancer therapy. Curr. Opin. Pharmacol. 2007; 7: 392–397
   PubMed Web of Science ®Google Scholar
• Dobra K., Andang M., Syrokou A., Karamanos N. K., Hjerpe A. Differentiation of mesothelioma cells is influenced by the expression of proteoglycans. Exp. Cell Res. 2000; 258: 12–22
   PubMed Web of Science ®Google Scholar
• Nilsonne G., Sun X., Nystrom C., Rundlof A., Potamitou K., Fernandes A., Bjornstedt M., Dobra K. Selenite induces apoptosis in sarcomatoid malignant mesothelioma cells through oxidative stress. Free Radic. Biol. Med. 2006; 41: 874–885
   PubMed Web of Science ®Google Scholar
• Sun X., Gulyas M., Hjerpe A., Dobra K. Proteasome inhibitor PSI induces apoptosis in human mesothelioma cells. Cancer Let. 2006; 232: 161–169
   PubMed Web of Science ®Google Scholar
• Gordon G. J., Mani M., Maulik G., Mukhopadhyay L., Yeap B. Y., Kindler H. L., Salgia R., Sugarbaker D. J., Bueno R. Preclinical studies of the proteasome inhibitor bortezomib in malignant pleural mesothelioma. Cancer Chemother. Pharmacol 2007
   PubMed Web of Science ®Google Scholar